Bing Yu1, Yan Zheng1, Jennifer A Nettleton1, Danny Alexander2, Josef Coresh3, Eric Boerwinkle4. 1. Division of Epidemiology, Human Genetics and Environmental Sciences, University of Texas Health Science Center at Houston, Houston, Texas; 2. Metabolon, Inc., Durham, North Carolina; 3. Departments of Epidemiology and Biostatistics, Johns Hopkins University, Baltimore, Maryland; and. 4. Division of Epidemiology, Human Genetics and Environmental Sciences, University of Texas Health Science Center at Houston, Houston, Texas; Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas Eric.Boerwinkle@uth.tmc.edu.
Abstract
BACKGROUND AND OBJECTIVES: Novel biomarkers that more accurately reflect kidney function and predict future CKD are needed. The human metabolome is the product of multiple physiologic or pathophysiologic processes and may provide novel insight into disease etiology and progression. This study investigated whether estimated kidney function would be associated with multiple metabolites and whether selected metabolomic factors would be independent risk factors for incident CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In total, 1921 African Americans free of CKD with a median of 19.6 years follow-up among the Atherosclerosis Risk in Communities Study were included. A total of 204 serum metabolites quantified by untargeted gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry was analyzed by both linear regression for the cross-sectional associations with eGFR (specified by the Chronic Kidney Disease Epidemiology Collaboration equation) and Cox proportional hazards model for the longitudinal associations with incident CKD. RESULTS: Forty named and 34 unnamed metabolites were found to be associated with eGFR specified by the Chronic Kidney Disease Epidemiology Collaboration equation with creatine and 3-indoxyl sulfate showing the strongest positive (2.8 ml/min per 1.73 m(2) per +1 SD; 95% confidence interval, 2.1 to 3.5) and negative association (-14.2 ml/min per 1.73 m(2) per +1 SD; 95% confidence interval, -17.0 to -11.3), respectively. Two hundred four incident CKD events with a median follow-up time of 19.6 years were included in the survival analyses. Higher levels of 5-oxoproline (hazard ratio, 0.70; 95% confidence interval, 0.60 to 0.82) and 1,5-anhydroglucitol (hazard ratio, 0.68; 95% confidence interval, 0.58 to 0.80) were significantly related to lower risk of incident CKD, and the associations did not appreciably change when mutually adjusted. CONCLUSIONS: These data identify a large number of metabolites associated with kidney function as well as two metabolites that are candidate risk factors for CKD and may provide new insights into CKD biomarker identification.
BACKGROUND AND OBJECTIVES: Novel biomarkers that more accurately reflect kidney function and predict future CKD are needed. The human metabolome is the product of multiple physiologic or pathophysiologic processes and may provide novel insight into disease etiology and progression. This study investigated whether estimated kidney function would be associated with multiple metabolites and whether selected metabolomic factors would be independent risk factors for incident CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In total, 1921 African Americans free of CKD with a median of 19.6 years follow-up among the Atherosclerosis Risk in Communities Study were included. A total of 204 serum metabolites quantified by untargeted gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry was analyzed by both linear regression for the cross-sectional associations with eGFR (specified by the Chronic Kidney Disease Epidemiology Collaboration equation) and Cox proportional hazards model for the longitudinal associations with incident CKD. RESULTS: Forty named and 34 unnamed metabolites were found to be associated with eGFR specified by the Chronic Kidney Disease Epidemiology Collaboration equation with creatine and 3-indoxyl sulfate showing the strongest positive (2.8 ml/min per 1.73 m(2) per +1 SD; 95% confidence interval, 2.1 to 3.5) and negative association (-14.2 ml/min per 1.73 m(2) per +1 SD; 95% confidence interval, -17.0 to -11.3), respectively. Two hundred four incident CKD events with a median follow-up time of 19.6 years were included in the survival analyses. Higher levels of 5-oxoproline (hazard ratio, 0.70; 95% confidence interval, 0.60 to 0.82) and 1,5-anhydroglucitol (hazard ratio, 0.68; 95% confidence interval, 0.58 to 0.80) were significantly related to lower risk of incident CKD, and the associations did not appreciably change when mutually adjusted. CONCLUSIONS: These data identify a large number of metabolites associated with kidney function as well as two metabolites that are candidate risk factors for CKD and may provide new insights into CKD biomarker identification.
Authors: Kathleen M Dungan; John B Buse; Joseph Largay; Mary M Kelly; Eric A Button; Shuhei Kato; Steven Wittlin Journal: Diabetes Care Date: 2006-06 Impact factor: 19.112
Authors: Vallabh O Shah; Raymond R Townsend; Harold I Feldman; Kirk L Pappan; Elizabeth Kensicki; David L Vander Jagt Journal: Clin J Am Soc Nephrol Date: 2012-12-06 Impact factor: 8.237
Authors: Melanie K Haroun; Bernard G Jaar; Sandra C Hoffman; George W Comstock; Michael J Klag; Josef Coresh Journal: J Am Soc Nephrol Date: 2003-11 Impact factor: 10.121
Authors: Kurt J Boudonck; Matthew W Mitchell; László Német; Lilla Keresztes; Abraham Nyska; Doron Shinar; Moti Rosenstock Journal: Toxicol Pathol Date: 2009-04 Impact factor: 1.902
Authors: Gesiane Tavares; Gabriela Venturini; Kallyandra Padilha; Roberto Zatz; Alexandre C Pereira; Ravi I Thadhani; Eugene P Rhee; Silvia M O Titan Journal: Metabolomics Date: 2018-02-27 Impact factor: 4.290
Authors: Casey M Rebholz; Morgan E Grams; Yuan Chen; Alden L Gross; Yingying Sang; Josef Coresh; Elizabeth Selvin Journal: Am J Epidemiol Date: 2017-10-15 Impact factor: 4.897
Authors: Julia Z Xu; Melanie E Garrett; Karen L Soldano; Sean T Chen; Clary B Clish; Allison E Ashley-Koch; Marilyn J Telen Journal: Am J Hematol Date: 2018-09-27 Impact factor: 10.047